"Toll-Like Receptor 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pattern recognition receptor that forms heterodimers with other TOLL-LIKE RECEPTORS. It interacts with multiple ligands including PEPTIDOGLYCAN, bacterial LIPOPROTEINS, lipoarabinomannan, and a variety of PORINS.
| Descriptor ID |
D051195
|
| MeSH Number(s) |
D12.776.543.750.705.910.500.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Toll-Like Receptor 2".
Below are MeSH descriptors whose meaning is more specific than "Toll-Like Receptor 2".
This graph shows the total number of publications written about "Toll-Like Receptor 2" by people in this website by year, and whether "Toll-Like Receptor 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 1 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2017 | 12 | 10 | 22 |
| 2018 | 9 | 8 | 17 |
| 2019 | 4 | 4 | 8 |
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Toll-Like Receptor 2" by people in Profiles.
-
SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1. Eur J Clin Invest. 2021 Nov; 51(11):e13661.
-
TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol. 2021 07; 22(7):829-838.
-
Cytotoxic T-lymphocyte elicited vaccine against SARS-CoV-2 employing immunoinformatics framework. Sci Rep. 2021 04 07; 11(1):7653.
-
Leveraging systems biology for predicting modulators of inflammation in patients with COVID-19. Sci Adv. 2021 02; 7(6).
-
Synthetic protein conjugate vaccines provide protection against Mycobacterium tuberculosis in mice. Proc Natl Acad Sci U S A. 2021 01 26; 118(4).
-
Reducing transmission of SARS-CoV-2 with intranasal prophylaxis. EBioMedicine. 2021 Jan; 63:103170.
-
Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model. EBioMedicine. 2021 Jan; 63:103153.
-
Inducible Epithelial Resistance against Coronavirus Pneumonia in Mice. Am J Respir Cell Mol Biol. 2020 10; 63(4):540-541.
-
4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor. Int J Mol Sci. 2020 Aug 19; 21(17).
-
Designing Multi-Epitope Vaccines to Combat Emerging Coronavirus Disease 2019 (COVID-19) by Employing Immuno-Informatics Approach. Front Immunol. 2020; 11:1663.